Two combination products in this catalogue pair compounds acting on the growth hormone axis: CJC / Ipamorelin and Tesamorelin / Ipamorelin. In each case the pairing puts two different receptor routes in one vial.
That is the interesting part structurally and the demanding part documentarily, because a certificate now has to establish two molecules rather than one.
Two receptor routes, not one mechanism
The compounds in these blends do not act through the same receptor. One route is a growth hormone releasing hormone analogue; the other is a ghrelin receptor agonist. They are grouped under one catalogue heading because they act on the same axis, not because they work the same way.
Growth hormone secretagogues explained covers the two routes and why compounds using different ones are not interchangeable.
What a blend certificate has to establish
| Panel | Strong version | Weak version |
|---|---|---|
| Identity | Both compounds confirmed independently | One confirmed, one inferred from the recipe |
| Purity | Reported per component | One combined figure |
| Ratio | Measured on the finished material | The intended ratio, restated |
| Content | Per component, each labelled | One number, no component named |
| Chromatogram | Two resolved peaks | A single peak |
Each field now has to be answered twice. A single figure for a two-compound vial answers half the question.
A single peak on a reversed-phase trace is the clearest sign a document cannot support per-component claims, because two compounds of different polarity should separate. Blends and single vials covers the reading.
The content line, and the usual misreading
On a blend certificate the content figure usually reports one component rather than the vial total, so a figure that looks like half the label is often correct. Reading it as the total produces a calculation wrong by roughly a factor of two.
Ask which component the figure describes if the document does not say, and record the answer against the lot. Net peptide content covers why content and label differ even on a single-compound vial.
What the fixed ratio costs
Flexibility. The proportion between components is set at manufacture and nothing downstream adjusts it, so a design that later calls for a different ratio cannot use the blend and the material has to be bought again as single vials.
That makes a blend the right purchase when the ratio is already settled by earlier work and the wrong one when it is still a variable. The convenience is real and it is paid for.
Naming, and what to confirm
Compounds on this axis circulate under research designations as well as common names, and listings mix them. A blend described only by two product names has not established which molecules are in the vial.
- The full name of each component, with any designation the supplier also uses.
- The sequence or a calculated mass for each.
- The certificate masses, which should agree.
- The salt form, which changes powder mass without changing either peptide.
Handling
The components differ in length and modification, so their individual handling profiles are not identical, and a blend has to be stored against whichever is more demanding. Reading handling from the category rather than from each sequence is the error to avoid.
The solvent also has to suit both compounds rather than one, which is a real constraint for a combination. Reconstitution solvents compared covers the options.
What to record
Both compounds by name in the same log entry, with the lot, the per-component content figures and the measured ratio where reported. A blend occupies one line while representing two materials, and an entry naming only the product cannot answer which were used.
Scope
Both CJC / Ipamorelin and Tesamorelin / Ipamorelin are supplied for laboratory research only. Nothing here describes effects in any organism.
In short
Two routes in one vial, and a certificate that has to prove both. Require identity and purity per component, a measured ratio, and two resolved peaks. Read the content line as one component. Buy a blend only when the ratio is already settled.
Comparing the two blends
Both pair a growth hormone releasing hormone analogue with a ghrelin receptor agonist, and the difference between them is which analogue is used. That changes the mass, the handling profile and the price, and it does not change what the certificate has to prove.
Choosing between them is a question about the research design rather than about documentation, and the documentation bar is identical for both. Growth hormone secretagogues explained covers what separates the two routes.
Storage, against the more demanding component
A blend has to be stored against whichever component is less forgiving, because the vial cannot be split. Where the two differ in length and modification, that is usually the longer or more heavily modified one.
Dry and sealed, both of these are comparatively robust. Once reconstituted, both elapsed time and the number of entries matter, and a blend used across several pieces of work tends to accumulate entries faster than a single-compound vial. Freeze-thaw cycles and aliquoting covers the fix.
On arrival
- Match the lot to its certificate, reading the full string.
- Confirm the certificate reports two identities rather than one plus an inference.
- Confirm which component the content figure describes.
- Inspect the cake, and record anything unexpected before the material is put away.
What to record
Both compounds named in the same log entry with the lot, the per-component content figures, and the measured ratio where reported. A blend occupies one line while representing two materials, and a record naming only the product cannot answer which were used.
Records to keep covers how the pieces tie together, and lot traceability covers why the lot is the field everything hangs off.
Where this sits
For combination products in general, blends and single vials. For the wider purchasing process, wholesale peptides for clinics.
Building the habit
The checks in this guide take minutes and they only work if they happen every time rather than when someone remembers. Two things make that realistic: a named person who owns receiving, and a form short enough that a busy day does not defeat it.
Writing an SOP for peptide receipt and storage covers turning the checks into something a practice actually follows, and chain of custody inside a practice covers the four points where the record usually breaks.
Why two routes in one vial is the interesting part
Because the pairing is deliberate rather than convenient. Combining compounds that act through different receptors is a research design choice, and it is the reason these products exist as blends rather than as a discount on buying two vials.
That also means the ratio carries more meaning than it would in an arbitrary combination, which is a further argument for requiring a measured ratio rather than a restated recipe.
Choosing a strength
Both blends are supplied across several strengths. Size against consumption rather than unit price, and remember that a blend is often drawn on more frequently than a single-compound vial, which makes entry count worth tracking alongside elapsed time.
What this guide does not cover
Anything about effects. These are research materials and nothing in a buying guide speaks to outcomes in any organism. What documentation settles is which two molecules are in the vial, in what proportion, and whether your lot is the one described.
Reading the quote
A wholesale quote carries four things: a unit price, a minimum quantity, the documentation included with the order, and the terms under which you pay. Only the first is read closely by most buyers and it is the one that tells you least about what the order will actually cost.
Documentation is the line that separates two identical-looking quotes, and terms change the real price more than the unit price does. Thirty days to pay on a four-figure order is worth roughly a month of the cost of capital. How to read a wholesale peptide quote takes all four apart.
Minimums, and what to do about them
A minimum order quantity is set by how material is manufactured rather than by a sales department. Synthesis runs at a batch scale and the cost is dominated by setup, purification and testing rather than by mass, so halving an order does not halve the cost.
Where the minimum exceeds what you can use before the material ages out, the honest responses are to order less often, consolidate across compounds so one order clears it, or drop the item from the formulary. Minimum order quantities covers which minimums move and which do not.
For a blend, confirm whether the minimum applies per line or per order, because a combination product is often the item that pushes an order over a threshold that single vials would not have cleared.
A short pre-order checklist
Five questions, one email, about fifteen minutes. Can you send the certificate for a lot I would actually receive. Which laboratory issued it and what is it accredited for. Which salt form is supplied. What is the lead time for in stock against made to order. And what happens if a lot is withdrawn after I have taken delivery.
The answers matter and so does how they arrive: how quickly, whether they address what was asked, and whether they come from someone who can see the document rather than relaying it. Auditing a peptide supplier is the longer version, and comparing suppliers on documentation covers weighing the replies against each other.
One last point. Where a practice uses both of these blends, document them as entirely separate materials rather than as variants of one product, because they contain different analogues at different masses and a shared record cannot later establish which was used.
For where this sits among the other molecules and formats a catalogue carries, not everything in a peptide catalog is a peptide covers how the classes differ.